Scientech Research LLC bought a new stake in shares of Bath & Body Works, Inc. (NYSE:BBWI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 31,197 shares of the company's stock, valued at approximately $1,210,000.
Several other large investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Bath & Body Works by 32.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,784 shares of the company's stock worth $2,046,000 after acquiring an additional 12,964 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Bath & Body Works by 5.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 88,423 shares of the company's stock valued at $3,428,000 after buying an additional 4,625 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new position in Bath & Body Works during the 4th quarter worth about $258,000. Charles Schwab Investment Management Inc. increased its holdings in Bath & Body Works by 13.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,704,625 shares of the company's stock worth $66,088,000 after purchasing an additional 195,813 shares in the last quarter. Finally, New Age Alpha Advisors LLC bought a new position in shares of Bath & Body Works in the 4th quarter valued at about $1,350,000. Institutional investors own 95.14% of the company's stock.
Bath & Body Works Stock Performance
BBWI stock traded down $0.15 during midday trading on Tuesday, reaching $33.43. The company's stock had a trading volume of 4,002,145 shares, compared to its average volume of 4,854,706. The firm has a market capitalization of $7.12 billion, a price-to-earnings ratio of 8.15, a PEG ratio of 0.92 and a beta of 1.87. Bath & Body Works, Inc. has a 1 year low of $24.96 and a 1 year high of $52.99. The stock has a fifty day simple moving average of $30.05 and a two-hundred day simple moving average of $34.03.
Bath & Body Works (NYSE:BBWI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $2.09 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.05. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. The business had revenue of $2.79 billion during the quarter, compared to the consensus estimate of $2.78 billion. As a group, analysts forecast that Bath & Body Works, Inc. will post 3.3 EPS for the current fiscal year.
Bath & Body Works announced that its Board of Directors has authorized a stock buyback program on Thursday, February 27th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued.
Bath & Body Works Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 20th. Shareholders of record on Friday, June 6th will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date is Friday, June 6th. Bath & Body Works's dividend payout ratio (DPR) is currently 21.98%.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Wells Fargo & Company lifted their price target on Bath & Body Works from $40.00 to $44.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. UBS Group boosted their price target on Bath & Body Works from $32.00 to $36.00 and gave the company a "neutral" rating in a research note on Tuesday. Piper Sandler set a $39.00 price target on Bath & Body Works and gave the company an "overweight" rating in a research note on Thursday, May 15th. JPMorgan Chase & Co. upped their price objective on shares of Bath & Body Works from $41.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday. Finally, Barclays upped their price target on shares of Bath & Body Works from $31.00 to $35.00 and gave the stock an "equal weight" rating in a report on Tuesday. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $42.56.
Read Our Latest Research Report on Bath & Body Works
Bath & Body Works Profile
(
Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
See Also
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
